fda glp-1 warning letters october 2025 The sent a letter to the maker of Ozempic and Wegovy over unreported potential side effects. Here's what to know FDA takes aim at Hims

have created an urgent need for advanced medical treatments, fueling rapid growth in both the anti-obesity medication and diabetes medication sectors

Elimination of the Coverage Gap The traditional coverage gap, often referred to as the donut hole, will be eliminated

Therefore, studies that extend the follow-up time and increase the sample size to observe the role of GLP-1 in atherosclerosis can be further developed

Moreover, over time, patients with T2DM have significantly faster progression of motor symptoms, worse depression scores, and are more likely to develop substantial gait impairment and mild cognitive impairment than patients without T2DM [53, 54]